Eastwood Bio-Medical Canada, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA27783W1059
CAD
1.00
-0.13 (-11.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Eastwood Bio-Medical Canada, Inc. stock-summary
stock-summary
Eastwood Bio-Medical Canada, Inc.
Pharmaceuticals & Biotechnology
Eastwood Bio-Medical Canada Inc. (EMBC) is a natural health supplement distribution company. The Company is engaged in the marketing and distributing natural health products in North America. It is a distributor of the Eleotin line of products, which include formulations based on natural ingredients. The Eleotin products include natural remedies for certain metabolic disorders, such as blood glucose disorders, hypertension and obesity. The Company's licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D for the development and maintenance of bones and teeth; Eleotin G2000 for cardiovascular health; Eleotin H55, a sedative and tension relief, Eleotin Zn330, which is involved in tissue formation and metabolism; Eleotin Bentley, which is used to promote healthy glucose levels, and Eleotin LBM, which is recommended for hypertension relief.
Company Coordinates stock-summary
Company Details
1130-4871 Shell Rd , RICHMOND BC : V6X 3Z6
stock-summary
Tel: 1 604 2472100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Yunji Kim
President, Chief Executive Officer, Company Secretary, Director
Mr. Ian Mallmann
Chief Financial Officer, Director
Dr. Marcus Kuypers
Independent Director
Dr. Terrance Owen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Apr 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 41 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

25.25%

stock-summary
Price to Book

-26.62